Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | TSPO | P30536 | 1/20 | 0.61 |
| ▸ | BRD2 | P25440 | 2/20 | 0.60 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.58 |
| ▸ | DNER | Q8NFT8 | 1/20 | 0.58 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3198871 | 0.93 | BRD4 (0.74) | BRD4ADORA3TSPOBRD2BRD3 | |
| SCHEMBL3189663 | 0.88 | BRD4 (0.72) | BRD4ADORA3TSPOBRD2BRD3 | |
| SCHEMBL2899729 | 0.87 | BRD4 (0.85) | BRD4ADORA3TSPOBRD2BRD3 | |
| SCHEMBL3197604 | 0.87 | BRD4 (0.77) | BRD4ADORA3TSPOBRD2BRD3 | |
| SCHEMBL3197791 | 0.87 | BRD4 (0.72) | BRD4ADORA3TSPOBRD2BRD3 | |
| SCHEMBL3189634 | 0.86 | BRD4 (0.73) | BRD4ADORA3TSPOBRD2BRD3 | |
| SCHEMBL3189720 | 0.86 | BRD4 (0.72) | BRD4ADORA3TSPOBRD2BRD3 | |
| SCHEMBL3199829 | 0.85 | BRD4 (0.69) | BRD4ADORA3TSPOBRD2BRD3 | |
| SCHEMBL3188289 | 0.85 | BRD4 (0.77) | BRD4ADORA3TSPOBRD2BRD3 | |
| SCHEMBL3190067 | 0.85 | BRD4 (0.79) | BRD4ADORA3TSPOBRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1887008-B1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-04-21 | — | — | EP | disclosed |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-1887008-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | ICOS, CD4, CD2 | BRD4 265/4885ADORA3 76/4885TSPO 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.